Navigation Links
Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study
Date:5/24/2011

ple worldwide. In the U.S. alone, more than 44 million men and women have osteoporosis or low bone-mineral density. Women in the U.S. over the age of 50 have a 50 percent risk of osteoporotic fracture in their remaining lifetimes. Twenty percent of hip-fracture patients enter long-term care, and 24 percent of hip fracture patients 50 years of age and older die within one year following their injury.

About Nordic Bioscience (www.nordicbioscience.com)

Nordic Bioscience is a privately owned biotechnology group with operations in Herlev, Denmark, and Beijing, China. With more than 20 years of experience in clinical research, Nordic Bioscience offers all aspects of scientific and regulatory consulting for clinical drug development programs, with a focus on osteoporosis and osteoarthritis. To further augment its service offerings, Nordic Bioscience has formed a strategic partnership with CCBR/SYNARC, a leading provider of medical image-analysis, subject-recruitment, and biochemical-marker services.

About Radius (www.radiuspharm.com)

Radius is a leading company developing a new generation of drug therapies for osteoporosis and women's health. BA058, Radius' novel, proprietary analog of PTHrP (parathyroid hormone-related protein), is in clinical development as a treatment for osteoporosis in two delivery options: BA058 Injection is a subcutaneous injection in Phase 3 clinical study; and the BA058 Microneedle Patch, currently in Phase 1 study, is a short wear-time, transdermal patch based on a microneedle technology from 3M Drug Delivery Systems that is intended to promote improved patient compliance and drive an expansion of the osteoporosis market. The company has a pipeline of additional drug candidate programs in earlier stages of development. Radius is located in Cambridge, Massachusetts.

Contact:'/>"/>

SOURCE Radius
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentation at Upcoming Conferences
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence
4. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
5. Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies
6. ShangPharma Announces First Quarter 2011 Results
7. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
8. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
9. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
10. ACT Announces Oregon Health & Science University as Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration
11. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Diagnostics Inc. (TSX:V: SQD), a life sciences company that ... advanced microarray diagnostics, today announced it has appointed ... team. In his capacity as CFO he will ... development stage to a commercially successful company including ... market strategy and to secure funding to drive ...
(Date:3/3/2015)... N.J. , March 3, 2015  Regenicin, Inc. ... company specializing in the development of and commercialization of ... tissues and organs, announced today that it has received ... with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... the Agreement, Amarantus made the final payments due to ...
(Date:3/3/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or ... Expert Opinion on Biological Therapy , Dr. Michael ... , at the Henry Ford Hospital in ... (TB4) has the capacity to promote CNS and peripheral ... leading to neurological recovery in each case.  They pointed ...
(Date:3/3/2015)... March 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, announced today that it will ... March 12, 2015 after the market close. The Company will ... day. Interested parties may access the call ... 756-4262 internationally, and using conference ID 98449349.  ...
Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Nov. 16, 2010 Reportlinker.com announces that a ... catalogue: Global Specialty Enzymes Industry ... This report analyzes the worldwide markets for Specialty ... segments - Specialty Medical Enzymes, Polymerases, Nucleases, and ...
... by researchers from Imperial College London, involves a new ... engineered to distort light or sound waves. With conventional ... with metamaterials, scientists can exploit a wealth of additional ... parts of the electromagnetic spectrum, an image can be ...
... 2010 Palatin Technologies, Inc. (NYSE Amex: PTN ... mimetic and small molecule agonist compounds with a focus on ... its first quarter ended September 30, 2010. Palatin reported a ... diluted share, for the quarter ended September 30, 2010, compared ...
Cached Biology Technology:Reportlinker Adds Global Specialty Enzymes Industry 2Reportlinker Adds Global Specialty Enzymes Industry 3Reportlinker Adds Global Specialty Enzymes Industry 4Reportlinker Adds Global Specialty Enzymes Industry 5Reportlinker Adds Global Specialty Enzymes Industry 6Reportlinker Adds Global Specialty Enzymes Industry 7Reportlinker Adds Global Specialty Enzymes Industry 8Reportlinker Adds Global Specialty Enzymes Industry 9Reportlinker Adds Global Specialty Enzymes Industry 10Reportlinker Adds Global Specialty Enzymes Industry 11Reportlinker Adds Global Specialty Enzymes Industry 12Reportlinker Adds Global Specialty Enzymes Industry 13Reportlinker Adds Global Specialty Enzymes Industry 14Reportlinker Adds Global Specialty Enzymes Industry 15Reportlinker Adds Global Specialty Enzymes Industry 16Reportlinker Adds Global Specialty Enzymes Industry 17Reportlinker Adds Global Specialty Enzymes Industry 18Reportlinker Adds Global Specialty Enzymes Industry 19Reportlinker Adds Global Specialty Enzymes Industry 20Reportlinker Adds Global Specialty Enzymes Industry 21Reportlinker Adds Global Specialty Enzymes Industry 22Reportlinker Adds Global Specialty Enzymes Industry 23Reportlinker Adds Global Specialty Enzymes Industry 24'Space-time cloak' to conceal events revealed in new study 2'Space-time cloak' to conceal events revealed in new study 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010 2Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010 4
(Date:2/5/2015)... Jan. 30, 2015  It is gratifying to see ... potential for genomic science as a means to better ... and treatment.  I was honored to participate in today,s ... medicine program. Since the 1980s my ... genomics—from the first sequenced genome of a free living ...
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)... Jan. 13, 2015 Technology Showcase, Hall E -   ... solutions, today announced it will showcase its EyeLock ID technology ... the Department of Energy,s Oak Ridge National Laboratory ... . EyeLock,s iris identity authentication technology is being used to ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... dramatically better computer tool for finding the genetic missteps ... Children,s Research Hospital Washington University Pediatric Cancer Genome ... help identify the chromosomal rearrangements and DNA insertions or ... is known as CREST, short for Clipping Reveals Structure. ...
... announces that a new market research report is available ... Microarrays and Lab-on-a-Chip http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html ... STUDY GOALS AND OBJECTIVES BCC,s goal ... current and emerging biochip technologies and products, and assess ...
... An outbreak of Escherichia coli causing a severe illness ... 2011 and has killed more than 20 people and sickened ... identified as a strain of E. coli O104:H4 ... to infection with E. coli O157:H7. Two isolates ...
Cached Biology News:Researchers improve method for finding genetic mistakes that fuel cancer 2Researchers improve method for finding genetic mistakes that fuel cancer 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15Two isolates from E. coli outbreak available 2
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
Laminin gamma-2 (G-16)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: